Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Buy" by Brokerages

Key Points

• Personalis, Inc. has received an average recommendation of "Buy" from five research firms, with a 12-month price target estimate of $7.42.
• The company recently reported a quarterly earnings per share of ($0.23), beating estimates, but had a negative net margin of 113.70%.
• Institutional investors own 61.91% of Personalis's stock, with significant increases in holdings from several firms, including ARK Investment Management and Geode Capital Management.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has been assigned an average recommendation of "Buy" from the five research firms that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have covered the stock in the last year is $7.4167.

PSNL has been the subject of several analyst reports. Wall Street Zen lowered shares of Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. HC Wainwright reiterated a "buy" rating and issued a $8.50 target price on shares of Personalis in a report on Monday, September 8th. Finally, BTIG Research set a $6.00 target price on shares of Personalis in a research report on Wednesday, August 6th.

Personalis Stock Down 1.0%

Shares of NASDAQ:PSNL opened at $5.87 on Wednesday. The firm has a fifty day moving average of $5.46 and a two-hundred day moving average of $4.89. The firm has a market capitalization of $520.55 million, a P/E ratio of -4.59 and a beta of 1.76. Personalis has a 12-month low of $2.83 and a 12-month high of $7.79.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts expect that Personalis will post -1.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC increased its holdings in shares of Personalis by 6.1% during the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company's stock worth $25,231,000 after purchasing an additional 412,762 shares during the period. AIGH Capital Management LLC increased its stake in Personalis by 4.5% in the first quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company's stock valued at $13,931,000 after acquiring an additional 169,884 shares during the period. Aberdeen Group plc increased its stake in Personalis by 3.2% in the second quarter. Aberdeen Group plc now owns 1,759,497 shares of the company's stock valued at $11,542,000 after acquiring an additional 54,713 shares during the period. Blue Water Life Science Advisors LP increased its stake in Personalis by 42.6% in the second quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company's stock valued at $10,997,000 after acquiring an additional 500,900 shares during the period. Finally, Geode Capital Management LLC increased its stake in Personalis by 165.6% in the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company's stock valued at $8,960,000 after acquiring an additional 851,422 shares during the period. Institutional investors own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.